UK markets closed

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3969-0.0219 (-5.23%)
At close: 04:00PM EDT
0.4167 +0.02 (+4.99%)
After hours: 07:02PM EDT

Aileron Therapeutics, Inc.

285 Summer Street
Suite 101
Boston, MA 02210
United States
617 995 0900
https://www.aileronrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees9

Key executives

NameTitlePayExercisedYear born
Dr. Manuel C. Aivado M.D., Ph.D.Pres, CEO & Director912.38kN/A1970
Dr. Vojislav Vukovic M.D., Ph.D.Sr. VP & Chief Medical Officer574.22kN/A1967
Ms. Susan L. Drexler C.P.A., M.B.A.Interim CFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1970
Dr. D. Allen Annis Ph.D.Sr. VP of ResearchN/AN/A1973
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Corporate governance

Aileron Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.